
Safety, Rehabilitation and Compensation (Defence-related Claims) (Specified Diseases and Employment) Instrument 2017
made under subsection 7(1) of the
Safety, Rehabilitation and Compensation (Defence-related Claims) Act 1988
Compilation No. 1
Compilation date: 20 September 2021
Includes amendments up to: F2021L01283
About this compilation
This compilation
This is a compilation of the Safety, Rehabilitation and Compensation (Defence-related Claims) (Specified Diseases and Employment) Instrument 2017 that shows the text of the law as amended and in force on 20 September 2021 (the compilation date). The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.
Uncommenced amendments
The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.
Application, saving and transitional provisions for provisions and amendments
If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.
Modifications
If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.
Self‑repealing provisions
If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.
Contents
1 Name…………………………………………………………………………………….. 1
3 Authority………………………………………………………………………………… 1
4 Definitions……………………………………………………………………………….. 1
5 Application-general……………………………………………………………………. 1
5A Application- firefighters……………………………………………………………… 1
6 Schedules……………………………………………………………………………...... 2
7 Specification…………………………………………………………………………… 2
Schedule 1—Specified diseases relating to specified employment 3
Schedule 2—Occupational asthma 11
Schedule 3— Specified diseases relating to firefighters 18
1 Name
This instrument is the Safety, Rehabilitation and Compensation (Defence-related Claims) (Specified Diseases and Employment) Instrument 2017.
3 Authority
This instrument is made under paragraph 7(1)(b) of the Safety, Rehabilitation and Compensation (Defence-related Claims) Act 1988.
4 Definitions
In this instrument:
Act means the Safety, Rehabilitation and Compensation Act 1988.
disease has its ordinary meaning.
ICD–10–AM reference, short for International Statistical Classification of Diseases and Related Health Problems, 11th edition, Australian Modification, means the reference in the alphanumeric coding scheme for diseases and external causes of injury set out in ICD–10–AM, as in force on 1 July 2019.
Note: The text of the ICD–10–AM, could in 2021, be viewed on the Independent Hospital Pricing Authority’s website, (http://www.ihpa.gov.au).
substance means any natural or artificial substance, whether in the form of a solid, liquid, gas or vapour.
5 Application-general
This instrument applies in relation to a disease specified in Schedule 1 that an employee sustains on or after the day this instrument commences.
5A Application–firefighters
(1) This instrument applies in relation to a disease specified in Schedule 3 that an employee sustains in relation to:
(a) the employee’s service as a firefighter; or
(b) the employee’s participation in a firefighter training course; or
(c) the employee’s role as an instructor of a firefighter training course;
at the RAAF Base Point Cook between 1 January 1957 and 31 December 1986.
(2) For the purposes of subsection (1), it does not matter whether the disease was sustained by the employee during the period mentioned in that subsection or at a later time.
6 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
7 Specification
(1) For the purposes of paragraph 7(1)(b) of the Act, a disease of a kind specified in column 1 of an item of the table in Schedule 1 is a disease related to employment of a kind specified in column 2 of that item.
(2) For the purposes of paragraph 7(1)(b) of the Act, a disease of a kind, including an aggravation of a disease of a kind, specified in column 1 of an item of the table in Schedule 3 by reference to the ICD–10–AM reference in column 2 of that item is a disease related to employment of a kind specified in column 3 of that item.
Schedule 1—Specified diseases relating to specified employment
| Column 1 | Column 2 |
Item | Disease | Employment |
Infectious diseases | |
1 | Anthrax | Employment involving work with: (a) animals; or (b) animal carcasses; or (c) animal parts. |
2 | Brucellosis | Employment involving work with: (a) animals; or (b) animal carcasses; or (c) animal parts; or (d) animal waste. |
3 | Hepatitis A | Employment involving work with human waste. |
4 | Hepatitis B or Hepatitis C | Employment involving work with human body fluids. |
5 | Human Immunodeficiency Virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS) | Employment involving work with: (a) needles in a healthcare services setting; or (b) sharps in a healthcare services setting. |
6 | Leptospirosis | Employment involving work with: (a) animals; or (b) animal carcasses; or (c) animal parts; or (d) animal waste. |
7 | Orf | Employment involving work with: (a) goats; or (b) goat carcasses; or (c) sheep; or (d) sheep carcasses. |
8 | Q-fever | Employment involving work with: (a) animals; or (b) animal carcasses; or (c) animal parts. |
9 | Tuberculosis | Employment involving work with: (a) animals: (i) in a farming setting; or (ii) in a veterinarian setting; or (b) animal carcasses: (i) in a farming setting; or (ii) in a veterinarian setting; or (c) human corpses: (i) in a healthcare services setting; or (ii) in a mortuary setting; or (d) persons (individuals) in a healthcare services setting. |
Malignant diseases |
10 | Primary malignant disease of the salivary gland | Employment for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation. |
11 | Primary malignant disease of the nasopharynx | Employment for at least 5 years (whether consecutive or not) involving work with: (a) formaldehyde; or (b) wood. |
12 | Primary malignant disease of the oesophagus | Employment for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation. |
13 | Primary malignant disease of the stomach | Employment for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation. |
14 | Primary malignant disease of the colon or rectum | Employment for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation. |
15 | Primary malignant disease of the liver | Employment for at least 5 years (whether consecutive or not) involving work with vinyl chloride monomer. |
16 | Primary malignant disease of the nasal cavity or para-nasal sinuses | Employment for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation; or (c) nickel; or (d) leather; or (e) wood. |
17 | Primary malignant disease of the larynx | Employment for at least 5 years (whether consecutive or not) involving work with: (a) asbestos; or (b) asbestos-containing material; or (c) acid mist (strong inorganic). |
18 | Primary malignant disease of the lung caused by asbestos | Employment for at least 5 years (whether consecutive or not) involving work with: (a) asbestos; or (b) asbestos-containing material. |
19 | Primary malignant disease of the bone | Employment for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation. |
20 | Primary malignant disease of the mesothelium | Employment for at least one year (whether consecutive or not) involving work with: (a) asbestos; or (b) asbestos-containing material. |
21 | Primary malignant disease of the breast | Employment for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation. |
22 | Primary malignant disease of the ovary | Employment for at least 5 years (whether consecutive or not) involving work with: (a) asbestos; or (b) asbestos-containing material. |
23 | Primary malignant disease of the kidney | Employment for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation; or (c) trichloroethylene. |
24 | Primary malignant disease of urothelial tissue lining the urinary tract | Employment for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation; or (c) 2-naphthylamine; or (d) benzidine; or (e) cyclophosphamide; or (f) ortho-toluidine; or (g) polycyclic aromatic hydrocarbons during aluminium production. |
25 | Primary malignant disease of the brain | Employment for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation. |
26 | Primary malignant disease of the thyroid | Employment for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation. |
27 | Primary leukaemia (excluding chronic lymphatic leukaemia) | Employment for at least 2 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation; or (c) benzene; or (d) butadiene; or (e) cyclophosphamide; or (f) formaldehyde. |
28 | Primary non-Hodgkins lymphoma | Employment for at least 2 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation. |
Diseases of the nervous system |
29 | Parkinson’s disease | Employment for at least one year (whether consecutive or not) involving work with manganese. |
30 | Peripheral neuropathy | Employment for at least one year (whether consecutive or not) involving work with: (a) acrylamide; or (b) arsenic; or (c) carbon disulphide; or (d) lead; or (e) mercury; or (f) n-hexane; or (g) organophosphates; or (h) trichloroethylene. |
Respiratory diseases | |
31 | Occupational asthma | Employment for at least 4 weeks (whether consecutive or not) involving work with an agent or thing specified in column 2 of an item of the table in Schedule 2. |
32 | Coal workers’ pneumoconiosis | Employment for at least 5 years (whether consecutive or not) involving work with coal. |
33 | Asbestosis | Employment for at least 5 years (whether consecutive or not) involving work with: (a) asbestos; or (b) asbestos-containing material. |
34 | Silicosis | Employment for at least 5 years (whether consecutive or not) involving work with: (a) material containing crystalline silica; or (b) silica. |
35 | Other pneumoconiosis | Employment for at least 5 years (whether consecutive or not) involving work with: (a) aluminium; or (b) barium; or (c) beryllium; or (d) cobalt; or (e) iron oxide; or (f) tin; or (g) tungsten. |
36 | Byssinosis | Employment for at least 4 weeks (whether consecutive or not) involving work with: (a) unprocessed cotton; or (b) unprocessed flax; or (c) unprocessed hemp; or (d) unprocessed sisal. |
37 | Extrinsic allergic alveolitis | Employment for at least 4 weeks (whether consecutive or not) involving work with: (a) feathers; or (b) grain; or (c) hay; or (d) straw. |
Hepatic disease |
38 | Non-infectious hepatitis | Employment involving work with: (a) acrylonitrile; or (b) alcohols; or (c) amino-derivatives of benzene; or (d) antimony; or (e) aromatic hydrocarbons; or (f) arsenic; or (g) benzene; or (h) benzoquinone; or (i) beryllium; or (j) cadmium; or (k) carbon disulphide; or (l) carbon monoxide; or (m) chromium; or (n) copper; or (o) fluorine; or (p) glycols; or (q) hexane; or (r) hydrogen cyanide; or (s) hydrogen sulphide; or (t) ketones; or (u) lead; or (v) manganese; or (w) mercury; or (x) methylene chloride; or (y) mineral acids; or (z) nitric acid esters; or (za) organochlorine compounds; or (zb) organophosphate; or (zc) osmium; or (zd) oxides of nitrogen; or (ze) ozone; or (zf) phosgene; or (zg) phosphorus; or (zh) selenium; or (zi) styrene; or (zj) thallium; or (zk) tin; or (zl) toluene; or (zm) toxic halogen derivatives of aliphatic; or (zn) toxic nitro-derivatives of benzene; or (zo) vanadium; or (zp) zinc. |
Skin diseases | |
39 | Irritant contact dermatitis | Employment for at least 4 weeks (whether consecutive or not) involving work and contact with: (a) alcohols; or (b) cutting fluids; or (c) cleaners; or (d) degreasers; or (e) disinfectants; or (f) liquids (frequent contact); or (g) liquids (prolonged contact); or (h) petroleum products; or (i) soaps; or (j) solvents. |
40 | Allergic contact dermatitis | Employment for at least 4 weeks (whether consecutive or not) involving work and contact with: (a) 2,5-diaminotoluene sulfate; or (b) 4-phenylenediamine base; or (c) ammonium persulfate; or (d) cobalt chloride; or (e) cocamide diethanolamide; or (f) coconut diethanolamide; or (g) colophonium/colophony/rosin; or (h) diazolidinyl urea; or (i) epoxy resin; or (j) formaldehyde; or (k) fragrance mix I: (i) amylcinnamaldehyde; or (ii) cinnamic alcohol; or (iii) cinnamic aldehyde; (iv) eugenol; or (v) geraniol; or (vi) hydroxycitronellal; or (vii) isoeugenol; or (viii) oakmoss absolute; or (l) fragrance mix II: (i) citral; or (ii) citronellol; or (iii) coumarin; or (iv) farnesol; or (v) hexyl cinnamic aldehyde; or (vi) hydroxyisohexyl 3-cyclohexene carboxaldehyde; or (m) glyceryl monothioglycolate; or (n) hydroxyethyl methacrylate; or (o) mercaptobenzothiazole; or (p) methyl chloroisothiazolinone; or (q) mixture of methylchloroisothiazolinone and methylisothiazolinone; or (r) nickel sulfate; or (s) potassium dichromate; or (t) quaternium 15; or (u) thiuram mix: (i) tetramethylthiuramdisulfide; or (ii) tetramethylthiuram monosulfide; or (iii) tetraethylthiuram disulfide. |
41 | Occupational vitiligo | Employment for at least 4 weeks (whether consecutive or not) involving work with: (a) hydroquinone; or (b) monobenzyl ether of hydroquinone; or (c) monobutyl ether of hydroquinone; or (d) para-amylphenol; or (e) para-tertiary-butylcatechol; or (f) para-tertiary-butylphenol. |
Musculoskeletal diseases |
42 | Raynaud’s disease | Employment for at least 12 weeks (whether consecutive or not) involving work with: (a) powered equipment that produces vibration; or (b) powered tools that produce vibration. |
43 | Bursitis at the elbow or knee | Employment for at least 6 months (whether consecutive or not) involving a work activity that: (a) for bursitis at the elbow: (i) involves prolonged external friction at or about the elbow; or (ii) involves prolonged external pressure at or about the elbow; or (iii) involves recurrent external friction at or about the elbow; or (iv) involves recurrent external pressure at or about the elbow; or (b) for bursitis at the knee: (i) involves prolonged external friction at or about the knee; or (ii) involves prolonged external pressure at or about the knee; or (iii) involves recurrent external friction at or about the knee; or (iv) involves recurrent external friction at or about the knee. |
Acute diseases |
44 | Acute poisoning or toxicity affecting the heart, lungs, liver, kidney, nervous system or blood | The same as for item 38. |
Schedule 2—Occupational asthma
| Column 1 | Column 2 |
Item | Class of agent or thing | Specified agent or thing |
1 | Arthropods | (a) acarian; or (b) barn mite; or (c) caddisfly; or (d) cricket; or (e) Ephestia kuehniella (Mediterranean flour moth); or (f) fowl mite; or (g) fruit fly; or (h) grain mite; or (i) flour mite; or (j) lesser mealworm; or (k) locust; or (l) sheep blowfly; or (m) silkworm. |
2 | Acids | (a) dodecanedioic acid; or (b) glacial acetic acid; or (c) hydrochloric acid; or (d) peroxyacetic acid; or (e) sulphuric acid; or (f) sulphur dioxide. |
3 | Acrylates | (a) acrylic acid; or (b) cyanoacrylates; or (c) methyl methacrylate; or (d) polymethyl methacrylate; or (e) trimethylolpropane triacrylate/2-hydroxypropyl acrylate. |
4 | Aldehydes | (a) formaldehyde; or (b) gluteraldehyde; or (c) paraformaldehyde; or (d) urea formaldehyde. |
5 | Amines | (a) aminoethyl ethanolamine; or (b) diethanolamine; or (c) dimethylethanolamine; or (d) ethanolamines; or (e) ethylenediamine; or (f) monoethanolamine; or (g) surfactant-specific amines; or (h) triethanolamine; or (i) triethylenetetramine; or (j) trimethylhexane-1; or (k) 6-diamine/isophorondiamine mixture. |
6 | Ammonias | (a) anhydrous ammonia; or (b) ammonium hydroxide; or (c) ammonia solution 10%; or (d) ammonia solution 29%. |
7 | Anhydrides | (a) hexahydrophthalic anhydride; or (b) himic anhydride; or (c) maleic anhydride; or (d) methyl tetrahydrophthalic; or (e) anhydride; or (f) phthalic anhydride; or (g) tetrachlorophthalic anhydride; or (h) trimellitic anhydride. |
8 | Bio-aerosols | (a) Alternaria; or (b) Chrysonilia sitophilia; or (c) Neurospora; or (d) Penicillium; or (e) cutting oils. |
9 | Biological enzymes | (a) Bacillus subtilis enzymes; or (b) bromelain; or (c) egg lysozyme; or (d) esperase; or (e) flaviastase; or (f) fungal amylase; or (g) fungal amyloglucosidase; or (h) fungal hemicellulose; or (i) pancreatin; or (j) papain; or (k) pepsin; or (l) trypsin. |
10 | Epoxy | (a) epoxy; or (b) epoxy adhesive. |
11 | Ethylene oxide | ethylene oxide. |
12 | Flours | (a) buckwheat flour; or (b) rye flour; or (c) soya flour; or (d) wheat flour. |
13 | Flowers | (a) baby’s breath; or (b) freesia; or (c) Limonium tataricum; or (d) sunflower. |
14 | Foods | (a) Brazil ginseng; or (b) castor bean; or (c) chamomile; or (d) cinnamon; or (e) Dioscorea batatas (Chinese yam); or (f) egg protein; or (g) fenugreek; or (h) garlic dust; or (i) green beans; or (j) guar; or (k) hops; or (l) paprika; or (m) pectin; or (n) rose hips; or (o) soybean lecithin; or (p) tea; or (q) thiamine (vitamin B); or (r) thyme. |
15 | Industrial cleaning and sterilising agents | (a) alkyl dimethyl benzyl ammonium chloride; or (b) benzyl-C10-16-alkyldimethyl, chlorides; or (c) benzyl-C12-16-alkyldimethyl, chlorides; or (d) benzyl-C12-18-alkyldimethyl, chlorides; or (e) benzyl-C16-18-alkyldimethyl, chlorides; or (f) benzyldimethylstearyl ammonium chloride; or (g) cetalkonium chloride; or (h) chlorhexidine; or (i) chlorine; or (j) dialkyl methyl benzyl ammonium chloride; or (k) dicumyl-peroxide; or (l) dodecyl dimethyl ammonium chloride; or (m) dimethyl ethyl benzyl ammonium chloride; or (n) dodecyl-dimethylbenzylammonium; or (o) fluorine; or (p) n-alkyl dimethyl benzyl ammonium chloride; or (q) persulphate salts; or (r) sodium hypochlorite; or (s) sodium metabisulfite. |
16 | Isocyanates | (a) diisocyanates; or (b) hexamethylene diisocyanate prepolymers; or (c) isocyanates; or (d) toluene diisocyanate prepolymers. |
17 | Latex | (a) latex; or (b) natural rubber. |
18 | Medications | (a) ampicillin; or (b) amprolium; or (c) cimetidine; or (d) codeine; or (e) colistin; or (f) hydralazine; or (g) ipecacuanha; or (h) hydrocodone; or (i) isonicotinic acid hydrazide; or (j) methyldopa; or (k) morphine; or (l) opiate compounds; or (m) oxycodone; or (n) papaverine; or (o) penicillamine; or (p) penicillins; or (q) phenylglycine acid chloride; or (r) psyllium; or (s) salbutamol intermediate; or (t) spiramycin; or (u) tetracycline; or (v) thebaine; or (w) tylosin tartrate; or (x) vancomycin. |
19 | Metals | (a) aluminium; or (b) aluminium chloride; or (c) aluminium oxide; or (d) aluminium compounds; or (e) ammonium dichromate; or (f) ammonium hexachloroplatinate (IV); or (g) chromium; or (h) chromium, metal; or (i) chromium, hexavalent; or (j) chromium, non-hexavalent; or (k) cobalt; or (l) cobalt compounds; or (m) nickel; or (n) nickel compounds; or (o) platinum; or (p) rhodium; or (q) soluble halogenated platinum compounds; or (r) titanium oxide/dioxide; or (s) tributyl tin oxide; or (t) tungsten carbide; or (u) tungsten carbide/cobalt; or (v) vanadium; or (w) welding fumes – gas metal arc welding on uncoated mild steel; or (x) welding fumes – stainless steel; or (y) stainless steel; or (z) zinc oxide. |
20 | Other reactive chemicals | (a) chlorofluorocarbon refrigerants heated; or (b) fluoride; or (c) furfuryl alcohol mixed with a catalyst; or (d) isolyzer; or (e) polyethylene terephthalate/polybutylene terephthal; or (f) polyfunctional aziridine; or (g) polypropylene heated; or (h) polyvinyl chloride heated; or (i) polyvinyl chloride non-heated; or (j) polyvinyl chloride thermally degraded; or (k) radiographic fixative; or (l) resin containing furfuryl alcohol; or (m) styrene; or (n) trigylicidyl isocyanurate. |
21 | Pesticides | (a) 3-amino-5-mercapto-1;2;4-triazole; or (b) acephate; or (c) chloramine T; or (d) chlorothalonil (bravo, echo); or (e) diazinon; or (f) dimethoate; or (g) fenthion; or (h) malathion; or (i) nemacur; or (j) piperazine; or (k) piperazine citrate; or (l) piperazine hydrochloride; or (m) pyrethrins; or (n) pyrfon; or (o) safrotin; or (p) tetramethrin. |
22 | Plants and sensitising agents or irritants derived from plants | (a) almond dust; or (a) Arabidopsis thaliana; or (b) Chlorella algae; or (c) gum arabic; or (d) henna; or (e) kapok; or (f) linseed oilcake; or (g) Pinellia ternata; or (h) quillaja bark; or (i) rice dust; or (j) tall oil crude; or (k) tall oil – rosin; or (l) tobacco leaf; or (m) tragacanth; or (n) turpentine; or (o) Vicia sativa (vetch); or (p) weeping fig. |
23 | Reactive dyes | (a) Cibachrome Brilliant Scarlet 32; or (b) Drimarene Brilliant Blue K-BL; or (c) Drimarene Brilliant Yellow K-3GL; or (d) Lanasol Yellow 4G; or (e) Levafix Brilliant Yellow E36; or (f) Methyl Blue; or (g) Rifacion Orange HE 2G; or (h) Rifafix Yellow 3 RN; or (i) Rifazol Black GR; or (j) Rifazol Brilliant Orange 3R. |
24 | Sensitising agents or irritants derived from animals | (a) bat guano; or (b) bovine serum albumin; or (c) casein; or (d) cat antigens; or (e) chicken antigens; or (f) cow antigens; or (g) frog antigens; or (h) guinea pig antigens; or (i) lactoserum; or (j) mice antigens; or (k) pig antigens; or (l) rabbit antigens; or (m) rat antigens. |
25 | Sensitising agents or irritants derived from fish or shellfish | (a) Anisakis simplex (herring worm) antigens; or (b) clam antigens; or (c) crab antigens; or (d) cuttlefish antigens; or (e) fishmeal; or (f) nacre dust; or (g) octopus antigens; or (h) prawn antigens; or (i) red soft coral antigens; or (j) salmon antigens; or (k) shrimp meal; or (l) trout antigens. |
26 | Soldering fluxes | (a) colophony soldering flux; or (b) alkyl aryl polyether soldering flux; or (c) zinc soldering flux. |
27 | Wood | (a) Triplochiton scleroxylon (African maple); or (b) Acacia melanoxylon (blackwood); or (c) Sequoia sempervirens (California redwood); or (d) Juglans olanchana (Central American walnut); or (e) Thuja occidentalis (eastern white cedar); or (f) Shoreal sp. (mahogany); or (g) Quercus robur (oak); or (h) Thuja lpicata (western red cedar). |
| | |
Schedule 3—Specified diseases relating to firefighters
| Column 1 | Column 2 | Column 3 |
Item | Disease | ICD–10–AM reference | Employment |
Skin diseases | | |
1 | Dysplastic naevus | D22/M8727/0 | Employment involving work relating to: (d) firefighting; or (e) participating in a firefighting training course; or (f) instructing participants in a firefighter training course; at RAAF Base Point Cook between 1 January 1957 and 31 December 1986. |
2 | Eczema or dermatitis | L20–L30 | The same as for item 1. |
Diseases of the nervous system | |
3 | Multiple sclerosis | G35 | The same as for item 1. |
4 | Parkinson’s disease | G20 | The same as for item 1. |
5 | Peripheral neuropathy | G62 | The same as for item 1. |
6 | Spinal muscular atrophy | G12 | The same as for item 1. |
7 | Erectile dysfunction | N48.4 | The same as for item 1. |
8 | Cauda equina syndrome | G95.9 | The same as for item 1. |
9 | Neurogenic bladder | N31.9 | The same as for item 1. |
10 | Non-alcoholic toxic encephalopathy | G92 | The same as for item 1. |
11 | Acquired colour vision deficiency | H53.5 | The same as for item 1. |
Mental diseases | |
12 | Depression | F32.0-F33.9, F34, F38 and F39 | The same as for item 1. |
13 | Sleep disorders with a neurological basis | G47.31 | The same as for item 1. |
14 | Bi-polar affective disorder | F31 | The same as for item 1. |
15 | Vertigo | R42 | The same as for item 1. |
16 | Memory loss | F04 | The same as for item 1. |
17 | Anxiety | F41 | The same as for item 1. |
18 | Panic disorders | F41.0 | The same as for item 1. |
19 | Impaired cognition | F03 | The same as for item 1. |
20 | Agoraphobia with panic disorder | F40.01 | The same as for item 1. |
Malignant diseases | |
21 | Malignant neoplasms | C00–C96 | The same as for item 1. |
22 | Myeloproliferative disorders | C81–C96, D45 and D47 | The same as for item 1. |
| | | | |
Liver diseases | |
23 | Liver disease (excluding diabetes) | K71 | The same as for item 1. |
24 | Pancreatic disease | K85–K86 | The same as for item 1. |
Gastrointestinal diseases | |
25 | Irritable bowel disorder | K58 | The same as for item 1. |
26 | Ulcerative colitis/Crohn’s disease | K50–K51 | The same as for item 1. |
27 | Diverticulitis | K57 | The same as for item 1. |
28 | Bowel polyps | D12 | The same as for item 1. |
Diseases of the immune system | |
29 | Mixed connective tissue disease | M35.1 | The same as for item 1. |
30 | Systemic lupus erythematosus | M32 | The same as for item 1. |
31 | Sarcoidosis | D86 | The same as for item 1. |
| | | | |
Endnotes
Endnote 1—About the endnotes
The endnotes provide information about this compilation and the compiled law.
The following endnotes are included in every compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.
Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.
If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.
Endnote 2—Abbreviation key
| o = order(s) |
ad = added or inserted | Ord = Ordinance |
am = amended | orig = original |
amdt = amendment | par = paragraph(s)/subparagraph(s) |
c = clause(s) | /sub‑subparagraph(s) |
C[x] = Compilation No. x | pres = present |
Ch = Chapter(s) | prev = previous |
def = definition(s) | (prev…) = previously |
Dict = Dictionary | Pt = Part(s) |
disallowed = disallowed by Parliament | r = regulation(s)/rule(s) |
Div = Division(s) | |
exp = expires/expired or ceases/ceased to have | reloc = relocated |
effect | renum = renumbered |
F = Federal Register of Legislation | rep = repealed |
gaz = gazette | rs = repealed and substituted |
LA = Legislation Act 2003 | s = section(s)/subsection(s) |
LIA = Legislative Instruments Act 2003 | Sch = Schedule(s) |
(md) = misdescribed amendment can be given | Sdiv = Subdivision(s) |
effect | SLI = Select Legislative Instrument |
(md not incorp) = misdescribed amendment | SR = Statutory Rules |
cannot be given effect | Sub‑Ch = Sub‑Chapter(s) |
mod = modified/modification | SubPt = Subpart(s) |
No. = Number(s) | underlining = whole or part not |
| commenced or to be commenced |
Endnote 3—Legislation history
Name | Registration | Commencement | Application, saving and transitional provisions |
Safety, Rehabilitation and Compensation (Defence-related Claims) (Specified Diseases and Employment) Instrument 2017 | 12 October 2017 (C2004L09749) | 12 October 2017 | - |
Safety, Rehabilitation and Compensation (Defence-related Claims) (Specified Diseases and Employment) Amendment Instrument 2021 | 17 September 2021 (F2021L01283) | 20 September 2021 | Sch 1 (item 9) |
Endnote 4—Amendment history
Provision affected | How affected |
s2 | rep LA s 48D |
s4 | am F2021L01283 |
s5 | am F2021L01283 |
s5A | ad F2021L01283 |
s7 | am F2021L01283 |
Sch 1 | am F2021L01283 |
Sch 3 | rep LA s 48C; ad F2021L01283 |
| |
| |